CORT Shareholder Notice: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss

Core Viewpoint - Corcept Therapeutics is facing a securities class action lawsuit following the FDA's rejection of its lead drug candidate, relacorilant, and a significant drop in its stock price, which erased nearly $2.5 billion in market capitalization in a single day [1][5]. Summary by Relevant Sections Lawsuit Details - The lawsuit, filed in the U.S. District Court for the Northern District of California, seeks to recover losses for investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025 [2]. - Investors are reminded that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026 [1][4]. Allegations Against Corcept - The complaint alleges that Corcept made materially false and misleading statements regarding relacorilant by failing to disclose critical information about the FDA's concerns [3][5]. - It is claimed that the company continued to promote Phase 3 results while being aware that the FDA considered the data fundamentally flawed [5]. Impact of FDA Communication - The FDA issued a Complete Response Letter (CRL) on December 31, 2025, stating it could not arrive at a favorable benefit-risk assessment for relacorilant due to an "insufficient" evidentiary record [5]. - The FDA had warned Corcept multiple times during pre-submission meetings in 2024 and early 2025 that its clinical data lacked sufficient evidence to support a New Drug Application (NDA) [5]. Stock Market Reaction - Following the disclosure of the FDA's CRL, Corcept's stock price fell from $70.20 on December 30, 2025, to $34.80 on December 31, 2025, marking a 50% decline [5].